Comparison Centre
Two compounds, the same questions, no cherry-picking
Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.
Sharing keeps the two compounds you picked.
How to read these scores
Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.
- Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
- Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
- Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
- Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
- Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.
None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.
LL-37
A human antimicrobial peptide studied topically for wound healing, now marketed for unrelated systemic uses.
Thymosin alpha-1
A thymic immune peptide approved in dozens of countries for specific indications, but never approved in the US — and marketed far beyond any approval.
How far human research has progressed
LL-37
Phase II/IIb topical wound studies completed; primary outcome not met in the larger studyThymosin alpha-1
Approved in multiple non-US regions for specific indications; studied in oncology and infectious disease settingsClaim-specific benefit evidence
A human exposure study or trial registration does not establish that the claimed benefit occurs.
LL-37
Not separately assessed; see the full profile.Thymosin alpha-1
Not separately assessed; see the full profile.Human research context
LL-37
Phase II/IIb topical wound studies completed; primary outcome not met in the larger studyThymosin alpha-1
Approved in multiple non-US regions for specific indications; studied in oncology and infectious disease settingsHuman efficacy evidence strength
Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
LL-37
Thymosin alpha-1
Preclinical (animal / lab) evidence strength
Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
LL-37
Thymosin alpha-1
Human safety evidence strength
Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.
LL-37
Thymosin alpha-1
Regulatory status (legal position, not proof it works)
LL-37
Check jurisdiction-specific details in the profile.
Not an approved medicine. Its clinical study history is topical, in hard-to-heal wounds. Injectable or systemic use for infections, 'immune reset' or biohacking purposes is unstudied. Compounding-nomination status has changed during 2026 and should be read cautiously.
Thymosin alpha-1
Check jurisdiction-specific details in the profile.
Not FDA-approved. The FDA's 2024 advisory review notes approvals in parts of Asia-Pacific, Latin America, Eastern Europe and the Middle East for various indications. Those approvals are region- and indication-specific; they do not generalise to 'immune boosting' in healthy people or to US availability.
Common claims
LL-37
- · Heals chronic wounds
- · Treats resistant infections
- · Resets or boosts the immune system when injected
Thymosin alpha-1
- · Boosts immune function
- · Adjunct benefit in hepatitis and some cancers
- · General immune 'optimisation' in healthy people
How settled our evidence rating is
LL-37
Thymosin alpha-1
Cancer-related questions raised by the biology
These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.
LL-37
Laboratory work reports both tumour-promoting and tumour-suppressing effects depending on tissue. Nothing is established in humans; the honest position is unresolved.Thymosin alpha-1
Studied as an immune adjunct in oncology settings — a therapeutic research context, not evidence it prevents or treats cancer as marketed online.What this adds up to, in plain English
LL-37
Preliminary human observations exist, but they may not establish a treatment-attributable benefit.Thymosin alpha-1
Preliminary human observations exist, but they may not establish a treatment-attributable benefit.A comparison is not a recommendation